ESMO 2019
ESMO 2019 Prostate Cancer
- ESMO 2019: Overall Survival Interim Analysis Results of the Phase 3 SPARTAN Trial
- ESMO 2019: Invited Discussant - Phase 3 PROfound Study for Metastatic Castration-resistant Prostate Cancer (LBA12)
- ESMO 2019: Treatment of Pelvic Node-Positive Prostate Cancer: Systemic Treatment: The Role of Chemotherapy and Androgen Receptor Targeted Therapy
- ESMO 2019: Treatment of Pelvic Node-Positive Prostate Cancer: Is there a Role for Radical Surgery?
- ESMO 2019: Treatment of Pelvic Node-Positive Prostate Cancer: Advances in Pelvic Nodal Radiotherapy
ESMO 2019 Kidney Cancer
- ESMO 2019: Invited Discussant: (911PD and 912PD) New Anti-Angiogenic Treatments for Kidney Cancer
- ESMO 2019: Patients with Advanced Renal Cell Carcinoma with Sarcomatoid Histology: A Subgroup Analysis on Efficacy and Biomarkers from the Phase 3 JAVELIN Renal 101 Trial of First-Line Avelumab plus Axitinib versus Sunitinib
- ESMO 2019: Results from a Global Patient Survey: Diagnosis, Management, and Burden of Renal Cell Carcinomas - A Medical Oncologist’s Perspective
- ESMO 2019: ADAPTeR: Anti-PD1 Therapy as Operative Therapy in Metastatic Renal Cell Carcinoma
- ESMO 2019: Results of the Phase 2 TRAXAR Study: A Randomized Phase 2 Trial of Axitinib and TRC105 (TRAX) versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma
ESMO 2019 Bladder Cancer
- ESMO 2019: Invited Discussant: IMvigor130: Phase III Study of Atezolizumab with or without Platinum-Based Chemotherapy in Previously Untreated Metastatic Urothelial Carcinoma
- ESMO 2019: EV-103 Enfortumab Vedotin plus Pembrolizumab for Urothelial Carcinoma
- ESMO 2019: Invited Discussant: How Do the Results of IMvigor130 Change Things in Bladder Cancer?
- ESMO 2019: Invited Discussant: Results of the IMVigor130 Study of Atezoluzumab as Monotherapy, or in Combination with Platinum Chemotherapy for Patients with Advanced or Metastatic Urothelial Carcinoma
- ESMO 2019: IMvigor130: Efficacy and Safety of Atezolizumab as Monotherapy or Combined with Platinum-based Chemotherapy vs Placebo + Platinum-based Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
ESMO 2019 Testicular Cancer
- ESMO 2019: Invited Discussant: Testicular and Kidney Cancer (913PD - APACHE (Testicular), 914PD (Testicular) , and 915PD (RCC))
- ESMO 2019: Prognostic Factors in Metastatic Seminomatous Germ Cell Tumors and Elevated HCG – a Study of the G3
- ESMO 2019: APACHE: An Open Label, Randomized, Phase 2 Study of Durvalumab, Alone or in Combination with Tremelimumab, in Patients with Refractory Germ Cell Tumors: Results from the Expanded Combination Therapy Cohort
- ESMO 2019: Prognostic Factors in Metastatic Seminomatous Germ Cell Tumors and Elevated Human Chorionic Gonadotrophin – Study of the G3
- ESMO 2019: APACHE: An Open Label, Randomized, Phase II Study of Durvalumab Alone or in Combination with Tremelimumab, in Patients with Refractory Germ Cell Tumors: Results from the Expanded Combination Therapy Cohort
